Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07321834 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate AI-09 In Participants With Glabellar Lines
A Phase 2 study of Glabellar Lines, sponsored by Eirion Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 5
- Study locations
NCT07321834 is a Phase 2 study of Glabellar Lines that is active but no longer recruiting, run by Eirion Therapeutics. The registered enrollment target is 68 participants, below the 397-participant average among 4 other Glabellar Lines trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT07321834, a Phase 2 study of Glabellar Lines, is active but no longer recruiting, sponsored by Eirion Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 5
- Study locations
Study Summary
Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of AI-09, a Ready-to-Use Liquid Injectable Botulinum Toxin.
Conditions Studied
Interventions
- BIOLOGICAL AI-09 Ready Use Injectable Botulinum Toxin
- BIOLOGICAL Vehicle
Study Locations (5)
Florida
- Center for Clinical and Cosmetic Research - Aventura
- Research Institute of the Southeast, Inc. - West Palm Beach
Louisiana
- Delricht Research - New Orleans
Tennessee
- Tennessee Clinical Research Center - Nashville
Texas
- Research Your Health - Plano
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07321834
The ClinicalTrials.gov registry entry for NCT07321834 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 397-participant average among 4 other Glabellar Lines trials with a reported enrollment target (83% lower). The listed sponsor is Eirion Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glabellar Lines appearing as the primary indexed condition, and to 2 interventions - of which AI-09 Ready Use Injectable Botulinum Toxin is the first listed.
NCT07321834 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Florida, Louisiana, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07321834 about?
NCT07321834 is a clinical study titled "A Study to Evaluate AI-09 In Participants With Glabellar Lines". Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of AI-09, a Ready-to-Use Liquid Injectable Botulinum Toxin.
What is the current status of trial NCT07321834?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2025-12-03. Estimated completion is 2026-02.
What conditions does trial NCT07321834 study?
This clinical trial studies the following conditions: Glabellar Lines.
What interventions are being tested in trial NCT07321834?
The interventions under investigation include: AI-09 Ready Use Injectable Botulinum Toxin (BIOLOGICAL), Vehicle (BIOLOGICAL).
Who is sponsoring clinical trial NCT07321834?
This trial is sponsored by Eirion Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07321834 being conducted?
This trial has 5 study locations across Florida, Louisiana, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glabellar Lines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
COMPLETED · Phase 1
-
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
COMPLETED · Phase 4
-
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
COMPLETED · Phase 3
-
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.